BioMarin Posts $122.8M Q3 Loss as Alesta Charge Hits Results
BMRN sits 17% above its 52-week low of $49.259.
Summary
BioMarin reported a third-quarter loss of $122.8 million, or 63 cents a share. The red ink lands right where the company pre-announced it would: an 8-K on October 6th flagged a roughly $283 million pre-tax in-process R&D charge from the Alesta Therapeutics acquisition, about $1.50 per share, so the loss is largely a known accounting hit rather than a fresh operational miss. Revenue came in at $1.025 billion, up 32% from a year earlier, against Q2, when sales rose 20% year-over-year to $990 million and management raised full-year guidance. Any guidance update is the piece that will decide the stock's reaction.
At the time of this announcement, BMRN was trading at $57.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $49.26 to $70.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.